JP2024532465A5 - - Google Patents

Info

Publication number
JP2024532465A5
JP2024532465A5 JP2024513759A JP2024513759A JP2024532465A5 JP 2024532465 A5 JP2024532465 A5 JP 2024532465A5 JP 2024513759 A JP2024513759 A JP 2024513759A JP 2024513759 A JP2024513759 A JP 2024513759A JP 2024532465 A5 JP2024532465 A5 JP 2024532465A5
Authority
JP
Japan
Prior art keywords
compound according
peg
pkkkrkv
independently
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024513759A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024532465A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/075693 external-priority patent/WO2023034818A1/en
Publication of JP2024532465A publication Critical patent/JP2024532465A/ja
Publication of JP2024532465A5 publication Critical patent/JP2024532465A5/ja
Pending legal-status Critical Current

Links

JP2024513759A 2021-09-01 2022-08-30 デュシェンヌ型筋ジストロフィーにおいてエクソン45をスキッピングするための組成物及び方法 Pending JP2024532465A (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US202163239671P 2021-09-01 2021-09-01
US63/239,671 2021-09-01
US202163244915P 2021-09-16 2021-09-16
US63/244,915 2021-09-16
US202163290960P 2021-12-17 2021-12-17
US63/290,960 2021-12-17
US202263298565P 2022-01-11 2022-01-11
US63/298,565 2022-01-11
US202263268577P 2022-02-25 2022-02-25
US63/268,577 2022-02-25
US202263337574P 2022-05-02 2022-05-02
US63/337,574 2022-05-02
US202263354454P 2022-06-22 2022-06-22
US63/354,454 2022-06-22
PCT/US2022/075693 WO2023034818A1 (en) 2021-09-01 2022-08-30 Compositions and methods for skipping exon 45 in duchenne muscular dystrophy

Publications (2)

Publication Number Publication Date
JP2024532465A JP2024532465A (ja) 2024-09-05
JP2024532465A5 true JP2024532465A5 (cg-RX-API-DMAC7.html) 2025-09-05

Family

ID=83945048

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024513759A Pending JP2024532465A (ja) 2021-09-01 2022-08-30 デュシェンヌ型筋ジストロフィーにおいてエクソン45をスキッピングするための組成物及び方法

Country Status (9)

Country Link
US (1) US20240417429A1 (cg-RX-API-DMAC7.html)
EP (1) EP4395831A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024532465A (cg-RX-API-DMAC7.html)
KR (1) KR20240099149A (cg-RX-API-DMAC7.html)
AU (1) AU2022337260A1 (cg-RX-API-DMAC7.html)
CA (1) CA3230279A1 (cg-RX-API-DMAC7.html)
IL (1) IL311138A (cg-RX-API-DMAC7.html)
MX (1) MX2024002365A (cg-RX-API-DMAC7.html)
WO (1) WO2023034818A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019165183A1 (en) 2018-02-22 2019-08-29 Entrada Therapeutics, Inc. Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2020028832A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
EP3830259A4 (en) 2018-08-02 2022-05-04 Dyne Therapeutics, Inc. MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2025038901A1 (en) * 2023-08-17 2025-02-20 Entrada Therapeutics, Inc. Cyclic peptides for delivering therapeutics
IL327379A (en) * 2023-09-26 2026-05-01 Entrada Therapeutics Inc Compounds and methods for skipping exon 50 in Duchenne muscular dystrophy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3149025T (pt) * 2014-05-21 2019-08-01 Entrada Therapeutics Inc Peptídeos penetrantes de células e métodos de fabrico e utilização dos mesmos
EP4058032A4 (en) * 2019-12-19 2024-01-10 Entrada Therapeutics, Inc. Compositions for delivery of antisense compounds
US20230111212A1 (en) * 2020-01-10 2023-04-13 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
KR20240009393A (ko) * 2021-03-31 2024-01-22 엔트라다 테라퓨틱스, 인크. 사이클릭 세포 침투 펩티드

Similar Documents

Publication Publication Date Title
JP2024532464A5 (cg-RX-API-DMAC7.html)
JP2021521140A5 (cg-RX-API-DMAC7.html)
JP7792371B2 (ja) GalNAc誘導体
JP2024524291A5 (cg-RX-API-DMAC7.html)
JP2024519601A5 (cg-RX-API-DMAC7.html)
JP2022535911A5 (cg-RX-API-DMAC7.html)
JP2021526796A5 (cg-RX-API-DMAC7.html)
JP2024518068A5 (cg-RX-API-DMAC7.html)
JP2022546609A5 (cg-RX-API-DMAC7.html)
JP2004537517A5 (cg-RX-API-DMAC7.html)
AU698210B2 (en) Polyamide-oligonucleotide derivatives, their preparation and use
JP2010505741A5 (cg-RX-API-DMAC7.html)
US20030207804A1 (en) Modified peptide nucleic acids
JP2014515762A5 (cg-RX-API-DMAC7.html)
JP2022095872A5 (cg-RX-API-DMAC7.html)
JP2018530560A5 (cg-RX-API-DMAC7.html)
WO2004024757A2 (en) Modified pna molecules
IL309001A (en) Antisense compounds and methods for targeting CUG repeats
JP2008509701A5 (cg-RX-API-DMAC7.html)
JP2002542341A5 (cg-RX-API-DMAC7.html)
JP2024518476A5 (cg-RX-API-DMAC7.html)
JP2011500814A5 (cg-RX-API-DMAC7.html)
CN107074911B (zh) 肽核酸单体和低聚体
JP2024511955A5 (cg-RX-API-DMAC7.html)
JP2024534786A5 (cg-RX-API-DMAC7.html)